The reported behaviour patterns, seen on a weekly basis, included rabbits biting the bars of their run or hutch repeatedly, fur pulling, biting, growling and hissing.
The charity says that with more than 680,0001 rabbits living alone, despite being highly sociable animals, and thousands more living in small hutches with no opportunity for exercise or mental stimulation, it is no surprise owners and vets are seeing these issues on a regular basis.
PDSA veterinary surgeon Rebecca Ashman said: "Our figures highlight that lack of mental stimulation can have a huge impact on pet behaviour. What’s most frustrating is the fact that many of these issues could easily be avoided if rabbits were given the right conditions, diet and companions to live alongside."
For this reason, PDSA is backing Rabbit Awareness Week’s #BuddiesForBunnies campaign to get solitary rabbits paired up with suitable companions from rescue centres. The charity says the findings should be a call to action for the 57% of rabbit owners who own single rabbits.
Rebecca added: "Pets do so much to enrich and improve our lives, but by not meeting their needs, their physical and mental wellbeing can be severely compromised. "Sadly, rabbits seem to be the forgotten pet". They can’t speak up and tell us if they’re unhappy, but with the right information and education, owners can make positive changes to their pets’ lives."
Reference
Called 24/7 Pet Hospital, the 10-part series will be broadcast every weekday morning at 10am until Friday 17 February.
Ben Harris, Wear’s Clinical Director, said: “Opening our doors to the BBC will help us to show the public what happens in a specialist veterinary hospital when a pet is unwell – and highlight the incredible care they receive by vets, nurses and support staff.
"The programme follows all aspects of our work, from initial consultations to the moment pets are reunited with their owners."
You will be able to view all 10 episodes on iPlayer here: https://www.bbc.co.uk/programmes/m001hz7n/broadcasts/upcoming.
The first is a new formulation of Sustain, which the company says will be the first UK veterinary product for cats to contain a prebiotic, probiotic and postbiotic.
The company has also launched Gomega for Cats, which contains a purified fish oil source of Omega 3 essential fatty acids which VetPlus says supports cardiovascular health and kidney function.
Jackie Marshall, Technical Advisor at VetPlus, said: “The launch of these two products will help our veterinary partners provide the best care for felines from gastrointestinal support through to aiding with renal and cardiac health.
Sustain for Cats and Gomega for Cats are now in stock and available from veterinary wholesalers.
www.vetplus.co.uk
RCVS CEO Nick Stace has published a refreshingly candid acknowledgement of recent concerns voiced by the profession on his blog, www.nickstaceblogs.org.
In his post, he gives a firm commitment to listen to the profession, asking just that in return, MsRCVS get more involved in College matters, such as voting in the elections and getting involved in consultations (starting with this one).
Definitely worth reading the full post: http://nickstaceblogs.org/2014/05/06/receiving-you-loud-and-clear/
Mark Bowen, Associate Professor at The University of Nottingham, has been appointed as President of the British Equine Veterinary Association (BEVA) for 2015/16.
Mark will take over the role from Andrew Harrison at the end of BEVA Congress on 12th September. Vicki Nicholls, Veterinary Assistant at Wright and Morten Vets, Cheshire becomes President Elect.
He said: "BEVA’s strengths lie in its members, who are committed to the welfare of the horse and the advancement of clinical practice. With new benefits for members, a new website, a new role for the BEVA Trust and the highest quality of education, BEVA is now an even more forceful and effective voice for the equine profession, both internally and externally.
"Whilst the profession attempts to shape its future for the next 15 years, we must continue to support the innovative individuals in the profession who look ‘outside the box’ and make sure that the future of our profession, the next generation of veterinary surgeons, does not become restricted by dogma and tradition; that they too can replicate the level of innovation seen in equine practice over the last 50 years.
"It is vital that we continue to strengthen our relationships with the British Horseracing Authority and contribute to the development of a funding body to replace the Horserace Betting Levy Board. Our relationship with the BVA, the regulation of allied professionals, the rescheduling of ketamine, the new EU animal health regulations and EU medicines regulations, even the role of Europe, are key areas where BEVA will make veterinary voices heard for the benefit of equine welfare.
"Lastly, employment and retention of veterinary graduates in the profession is a cause of concern to us all. Over the next year we will enhance the Internship Awareness Programme and provide support and mentoring for the younger members of the profession. BEVA council is full of individuals committed to working on your behalf and I am looking forward to working alongside them all for the benefit of us all."
The weekly sessions will offer practical guidance for veterinary surgeons and nurses about how they can manage chronic cases in line with guidelines issued by the Royal College of Veterinary Surgeons, the British Veterinary Association and the government.
Dechra’s Veterinary Technical Advisor Emily Casey BVM&S MRCVS will present the first webinar tackling Addison’s disease on Thursday April 2 from 1pm to 2pm and again from 7pm to 8pm. It will be available to watch again or download via the Dechra Academy.
It will include advice on how to stabilise patients and administer Zycortal while respecting government guidelines, including prioritisation of blood testing, use of telemedicine and provision of additional owner support. Each webinar represents one hour of CPD.
Dechra’s Technical Services Manager Jamie Walker said: “Since the outbreak of coronavirus began, we have received a large number of calls from practices wanting advice and guidance on how they should be managing chronic cases at this time.
"Our case management webinars will offer practical advice on a number of common small animal issues and aim to provide reassurance and support to veterinary professionals at this challenging time."
Further webinars will be held each Wednesday in April.
To register for the free webinars visit www.dechra.co.uk/events.
Led by Aarti Kathrani, a senior lecturer in small animal internal medicine at the Royal Veterinary College, and Jennifer Larsen, Professor of Clinical Nutrition at the University of California School of Veterinary Medicine, the presentation will focus on how veterinary professionals in general practice can manage nutritional recommendations for patients that have two or more health conditions with competing or overlapping nutritional needs.
During the webinar, Aarti and Jennifer will share practical insights into making effective clinical decisions when selecting diets for patients with multiple conditions and reflect on how this can support the management of these cases.
They will explore scenarios where the optimal diet for one condition may not be suitable for a concurrent condition, requiring clinicians to prioritise.
The speakers will also address how nutrition and feeding management can be modified to ensure medication delivery without compromising therapeutic efficacy.
The webinar will also address the issue of pet owners seeking non-veterinary recommendations or relying on internet research for advice (something which apparently 78.6% of pet owners do1).
https://webapp.spotme.com/login/eventspace/CollaborativeCareJuly2023
Medivet, the practice group which is to feature in the forthcoming Panorama documentary It shouldn't happen at a vets' (9pm, July 22nd), has issued a statement concerning the programme.
The statement, which can be read in full here, includes an interview with a Medivet client who was in turn interviewed for the documentary:
Looking at the imagery on the company's website, I'm not altogether sure I'll be able to resist it either.
The new range, which comes in chicken or tuna flavour with vegetables and rice, includes:
Urinary Care - to help dissolve struvite uroliths
Derm Defense - to support skin health
Digestive Care - for pets with gastrointestinal disorders and pets in recovery
Metabolic - a weight management diet for pets
Kidney Care - to support pets with kidney conditions
For more information, visit: https://www.hillspet.co.uk/prescription-diet/stew.
Dechra Veterinary Products has introduced two additional new products to its Veterinary Essentials range: Alvegesic vet and Clavudale.
Alvegesic vet contains butorphanol, a well-known and widely used drug for sedation, anaesthesia and analgesia in both dogs and cats. In horses, Alvegesic vet is indicated for analgesia and sedation.
Alvegesic vet is available in 10ml multidose vials and is licensed for administration by intravenous, intramuscular or subcutaneous routes, depending on indication, in both cats and dogs.
The other new addition to the Veterinary Essentials range is Clavudale, which contains the broad spectrum antibiotic amoxicillin, potentiated with clavulanic acid. Clavudale is bactericidal, active against a wide variety of bacterial organisms, including gram-positives and gram-negatives.
Clavudale is effective in treating a wide range of bacterial diseases of cats and dogs. These include: skin disease; soft tissue infections; dental infections; urinary tract infections; respiratory disease and enteritis. Clavudale is supplied in boxes of 24 tablets, with 4 blister strips of six tablets.
Further information on Alvegesic vet and Clavudale is available by calling Liz Rawlings at Dechra on 01743 441 632 or visiting www.dechra.com
The RCVS Disciplinary Committee has directed that a veterinary surgeon from Berkshire be removed from the Register, following his administration of a prohibited substance to a racehorse and his subsequent attempts to conceal his actions.
At a six-day hearing that concluded yesterday, James Main, a partner in the O'Gorman, Slater, Main & Partners veterinary practice in Newbury, and former lead veterinary surgeon to racehorse trainer Nicky Henderson, faced four charges of serious professional misconduct concerning his treatment of Moonlit Path, a six-year-old mare owned by The Queen.
Three of the charges related to Mr Main breaching British Horseracing Authority (BHA) rules by injecting Moonlit Path with tranexamic acid (TA) on the day she was due to race; the fourth charge related to his dishonest concealment of this treatment in his practice clinical records. Nicky Henderson had himself faced a BHA Inquiry into this case in 2009 and subsequently been sanctioned.
The Committee heard that on 18 February 2009, Mr Henderson's yard requested a veterinary surgeon attend Moonlit Path to administer an injection of Dycenene the following morning. The injection was requested as the mare was prone to exercise-induced pulmonary haemorrhage. Mr Main attended on the morning of 19 February and injected the horse with intravenous tranexamic acid. Moonlit Path raced at Huntingdon later that day, along with the eventual winner, and favourite, Ravello Bay - another horse trained by Mr Henderson. Moonlit Path finished sixth and a urine sample taken from her after the race tested positive for TA.
Of the four charges, Mr Main admitted injecting Moonlit Path with TA on the day she was due to race when he knew this breached the BHA's rule prohibiting any substance other than the horse's usual feed and water being given on race day. However, Mr Main denied knowing that, if tested, a horse would test positive for TA (thereby imposing a strict liability on the trainer); he denied administering a prohibited substance to a horse with the intention to affect that horse's racing performance; and, he denied dishonestly concealing the TA injection by omitting it from his clinical records and referring to it as a 'pre-race check'.
The Committee heard and carefully considered evidence from Mr Henderson and his employees, from BHA investigating officers and its Director of Equine Science and Welfare, from an expert equine physiologist and from Mr Main himself. In its findings, the Committee stated it was "unimpressed by Mr Henderson's evidence and surprised by his apparent lack of knowledge of the rules of racing".
Whilst the Committee accepted Mr Main believed at the time that Moonlit Path would not test positive for TA, it considered he failed to fully inform himself of the medicinal product he was using; especially so as TA does not possess a Marketing Authorisation as a veterinary medicinal product. In so doing, he did not meet his professional obligation to provide Mr Henderson with the information and advice he needed.
The Committee concluded that TA was a prohibited substance and, whilst accepting that Mr Main's concern had solely been for Moonlit Path's welfare, he had actually breached BHA rules by affecting her performance through administering such a substance.
Finally, the Committee found that Mr Main had deliberately concealed the TA injection to Moonlit Path by describing it in his notes as a 'pre-race check' - a protocol developed over several years between the practice and Mr Henderson. Such inaccurate clinical records were in breach of the RCVS Guide to Professional Conduct and led the Committee to conclude he had acted dishonestly. The Committee also found Mr Main "did not act with candour" by claiming to have administered the TA injection the day before the race. On questioning by the Legal Assessor, however, he admitted that he had known that Moonlit Path was racing the same day that he administered the injection.
Professor Sheila Crispin, chairing the Committee, said: "[We] regard it as wholly unacceptable practice that a veterinary surgeon should be party to serious breaches of rules of another regulatory body in the field of animal welfare ... and which go to the very integrity of racing.
"Whilst the findings relate to a single incident, [we] are satisfied that Mr Main's actions amounted to pre-meditated misconduct ... It is highly relevant that Mr Main held positions of responsibility within the racing industry where he was required to uphold the rules and standards of the profession," she added.
Noting Mr Main's "long and hitherto unblemished career as a highly respected equine veterinary surgeon", the Committee accepted Mr Main's evidence that the reason for the administration of tranexamic acid was solely his concern about the welfare of the horse. Nevertheless, it found his evidence was "evasive, lacking in candour and on some aspects of the case his evidence was untrue".
Professor Crispin concluded: "...proven dishonesty has been held to come at the top end of the spectrum of gravity of disgraceful conduct in a professional respect ... Having considered carefully all the mitigation put forward on Mr Main's behalf, [we] have concluded that Mr Main's behaviour was wholly unacceptable and so serious that removal of his name from the Register is required."
For every 'Proud to support Dogs for Good' profile picture changed and tagged with @PetMagicMoments and #dogsaregood, Elanco will donate £1 to the charity that trains dogs to give life-changing assistance to people with disabilities.
The company is hoping to raise up to £5,000 for its long-term charity partner through the Pet Magic Moments - https://www.facebook.com/PetMagicMoments/ - Facebook picture initiative, with an overall aim of raising in excess of £15,000 in total for Dogs for Good to support the training of three assistance dogs.
Elanco says it will raise additional money through fundraising activities and employees will also be encouraged to carry out voluntary work to support Dogs for Good in the three days a year they are given to volunteer for worthwhile charities.
Matthew Rowe, marketing manager at Elanco Animal Health, said: "Our Dogs for Good Facebook picture initiative will help highlight the profile of this wonderful and inspiring charity, while raising funds to support the training of an assistance dog."
Dogs for Good (the new name for Dogs for the Disabled) is an innovative charity, exploring ways dogs can help people overcome specific challenges and enrich and improve lives and communities.
Its assistance dogs support adults and children with a range of disabilities and also children with autism. It trains activity and therapy dogs to work with specialist handlers in communities and schools and its Family Dog team also gives specialist advice and support to help people get the most out of their relationship with their pet dog.
For further information about the charity, visit www.dogsforgood.org or call on 01295 252600.
They say this approach could lead to a reduction in the number of vaccines that need to be administered to each bird.
Vaccines that target multiple diseases are in high demand due to the many viruses that can circulate simultaneously in flocks. Protecting against the most dangerous diseases with one vaccine could reduce overall vaccination costs for poultry producers and decrease the number of times that birds need to be handled.
The researchers demonstrated that a gene editing system called CRISPR/cas9 can be used to insert a gene of the IBD virus into the currently used Marek’s disease vaccine virus. The added genetic material protects poultry against IBD in addition to the protection already offered by the Marek’s disease vaccine, meaning that bird owners would only need to use one vaccine instead of two.
Other vaccines generated by conventional methods can achieve a similar result, but by using the CRISPR/cas9 system the Pirbright researchers say they have been able to insert the IBD gene far more quickly, easily and accurately than the methods that have been used before. This will significantly reduce the time needed to generate new vaccines.
Professor Venugopal Nair, joint leader of the research at Pirbright said: "The method we have created with CRISPR/cas9 really increases the scope of how we edit the Marek’s disease vaccine to include other virus components. Now we have shown that the gene-edited vaccine protects against both Marek’s disease and IBD, we are looking at inserting more genes from other viruses."
The team intend to generate a vaccine that will be able to protect against multiple avian diseases and will next target two high consequence poultry viruses - avian influenza virus and the Newcastle disease virus. The flexibility of the new method also means that as the viruses evolve, the vaccine virus can be easily edited to include new genes which protect against emerging strains.
The Pirbright Institute says there has been huge commercial interest in using this technology to develop novel vaccines, so it intends to partner vaccine manufacturing companies to bring CRISPR/cas9 edited vaccines to market.
This scientific paper can be found in the Vaccine journal and was funded by the Biotechnology and Biological Sciences Research Council (BBSRC); grant numbers BB/P016472/1 BB/L014262/1.
Photo: Cells infected with the Marek's disease vaccine virus, HVT, (green) expressing the inserted infectious bursal disease virus gene, VP2 (red). Cell nuclei are shown in blue. © Dr Na Tang, The Pirbright Institute 2018.
Jason (pictured right with Paul), said: "Let me tell you, that was hard! Nine days and 900km of mountain bike riding, with 250km technical single track and only about 10 km tar, but we did it! We are so proud to be able to contribute to a future for rhinos!"
The veterinary velocipedists were raising money for The Chipembere Foundation, which specialises in sourcing, testing and funding technology for monitoring rhinos. They fund K9 handlers and their tracking and apprehension dogs, as well as funding and providing anti-poaching teams with vital equipment needed to translocate rhinos across Southern Africa.
It costs about £38000 to translocate a rhino from South Africa to neighbouring Botswana where there is less poaching (for now). Satellite tracking leg collars cost £1500 with an annual service and VHF collars and transmitters costing around £220. Dog and dog handler training is in the region of around £5000 per dog and there are additional costs for kennels, transport vehicles and day to day items like bowls, brushes, leads etc.
If you want to support Jason and Paul in their efforts to make a positive difference to the plight of the fast-dwindling numbers of rhino, visit www.justgiving.com/teams/rhinocycle.
The company points out that poisoning cases rise dramatically over Christmas, when food that is poisonous to dogs is more likely to be left out and owners are more relaxed (is that a euphemism, TVM?).
For that reason, the Emedog bumper pack contains 20 x 1ml single use vials - four times more than the regular pack and retails at £251.76 a saving of 10% compared to purchasing four regular packs.
Dosage is one vial injected subcutaneously per 10kg and vials have a three-year unopened shelf life, which should minise wastage.
Will Peel MRCVS, Product Manager at TVM UK said: "The number of poisoned animals seen by vets rises dramatically over the festive season so it’s vital that vets have enough product to see them through this time. The Emedog bumper pack will ensure that they are prepared for Christmas with the resources they need to deal with such cases."
The Emedog bumper pack is available from November 2019 from all veterinary wholesalers.
The study1 investigated the effects of a weight loss programme on biochemical and immunological profile, blood leptin level, and cardiovascular parameters in a cohort of dogs with naturally occurring obesity, in order to address the effects due to the imbalance of these aspects on the clinical presentation and management of canine obesity.
For the study, eleven obese but otherwise healthy dogs were included in a six-month weight loss programme, together with a control group of eleven healthy dogs at ideal body condition.
After the six-month weight loss programme, the obese dogs showed clinical improvements on a number of key indicators related to immune function, such as reduced tumour necrosis factor (TNF)-α and interleukin (IL)-6, known to impair insulin action in metabolic tissues but also favour cancer development in humans. Ten out of eleven showing a reduced BCS and no longer classified as obese.
Ten out of eleven dog owners also reported that their dogs were more active and that their quality of life had notably improved.
Hugues du Plessis, Pet Obesity Prevention Manager, at Purina said: “Preventing pet obesity is a major focus at Purina. We not only want to be providing pet owners with information on the benefits of a healthy pet lifestyle, but we also want to help them achieve it. This is why we are working with partner organisations to understand how behavioural science can be used to support owners, from the recognition of an issue, to the changes that will make a difference".
Reference:
Rexxolide contains 100 mg/ml of tulathromycin, which is widely used to treat BRD and SRD. It also has a single dose and low injection volume of 1 ml/40 kg BW, to make it more convenient.
Dechra says Rexxolide has an immune-modulating and anti-inflammatory action and offers equal viscosity and syringability as other products on the market1. It can be used for treatment and metaphylaxis of BRD and SRD and offers early-stage treatment for infectious pododermatitis.
Dechra’s Equine and Food Producing Animal Brand Manager, Emma Jennings said: “Launching Rexxolide into the market provides an alternative option to existing BRD, SRD and foot rot treatments for farm vets across the UK and Ireland.
"We support an integrated approach to the control of BRD, with good husbandry, early detection and correct therapy being vital tools in managing the multi-factorial condition."
Rexxolide is available in 50ml and 100ml vials. For more information visit www.dechra.co.uk.
The AHT has published the first research paper of its kind which looks at idiopathic epilepsy (IE) in the Italian Spinoni, a breed where the prevalence of IE has been found to be 5.3%, compared to 0.6% estimated to be seen in dogs generally in UK first opinion practice.
Dr Luisa De Risio, Head of Neurology at the AHT and lead researcher on the paper, said: "Idiopathic epilepsy is the most common chronic neurologic disorder in dogs but it can be more common in some breeds than others, for example Irish Wolfhounds, Border Collies and Italian Spinoni. Sadly, we see a lot epileptic dogs in our clinic, including these breeds as well as Golden Retrievers and Labrador Retrievers, so research being undertaken at the AHT, and around the world, is very important in helping owners of dogs with epilepsy to be able to control the effects of the disease.
"The Italian Spinone is a wonderful breed but is highly affected by idiopathic epilepsy. To our knowledge, no one has conducted such a large-scale research study in this breed to be able to gain a better understanding of how the epilepsy manifests, how prevalent it really is and, importantly, which factors may contribute to survival in these dogs.
"With the backing of the Italian Spinone Club of Great Britain, the AHT was able to design a questionnaire for the research study and work with the Kennel Club to invite over 3,000 Kennel Club registered Italian Spinone owners to aid our research by completing the questionnaire.
"1,192 owners participated in the research and of this sample, 63 Italian Spinoni had IE. Owners of affected dogs were then invited to complete a further questionnaire and asked to make the dog's medical records available. This gave us a very large amount of data to analyse from which we were able to glean a lot of very useful information about the clinical characteristics of idiopathic epilepsy in Italian Spinoni."
The research also looked at survival times of those dogs in the study with IE. Survival was significantly longer in Italian Spinone with no cluster seizures and in Italian Spinone in which antiepileptic medication was initiated after the second seizure rather than after more than three seizures.
Luisa continued: "From this sample we were able to conclude that idiopathic epilepsy in this breed often has a severe presentation but starting treatment with antiepileptic medication after the second seizure, and aggressive treatment of cluster seizures, may improve the survival of these dogs.
"The input in treatment design and modulation by a specialist veterinary neurologist with expertise in canine epilepsy can help to optimise treatment success and the dog's quality of life.
"We hope these findings will help to increase veterinary knowledge and understanding of this horrible disease and give Italian Spinoni, and other affected breeds, the best chance of fighting IE.
"Epilepsy is one of the most complex and difficult diseases to treat, with several variables in any case, but it is important for owners not to give up hope and to seek a consultation with a veterinary neurologist who specialises in epilepsy, if possible."
The next phase of the AHT's research in the Italian Spinone is to identify the genetic basis of this condition, with the aim of identifying the genetic mutations responsible so that a genetic test could be created. This research is currently on-going in Italian Spinoni and Border Collies and requires more DNA samples from affected and unaffected dogs.
Luisa said: "A genetic test is the only way to successfully help breeders identify carriers and select matings which are most likely to produce unaffected dogs. However, the genetics, like the condition itself, are very complex so the development of such a test is still likely to be many years away. The most we can do for these lovely dogs now is to share these findings across the veterinary profession and to do our best to treat each dog as well as we can."
The full paper is titled 'Idiopathic Epilepsy in the Italian Spinone in the United Kingdom: Prevalence, Clinical Characteristics, and Predictors of Survival and Seizure Remission' and is published in the Journal of Veterinary Internal Medicine on an open-access basis.
Photo: © Caroline Granycome
The announcement comes as as findings from the BVA’s Voice of the Veterinary Profession survey showed that 45% of vets under 35 had concerns about their mental health in the last year. While under-35s were among the most likely to seek support, half of veterinary surgeons under 35 with concerns did not seek support and 45% of all vets reported that they weren’t sure, or could not recognise, the signs of mental ill health in a colleague.
A Vet Futures survey found that recent graduates actively look for and want supportive working environments in the early stages of their careers, with two out of five students and young graduates rating a ‘supportive workplace’ as a key factor in influencing career choice.
However, in the BVA’s Voice of the Profession survey, 70% of young vets said they did not feel supported in their professional development phase (PDP) during their first year of employment, indicating that more needs to be done across the veterinary profession as a whole to provide such supportive environments. The survey also revealed that 69% had no appraisal, 82% had no mentor and 77% had no time within standard hours of work to update their PDP record and case notes, with over half having none of these.
The BVA says it is investing in the Young Vet Network (YVN) to support recent graduate groups and help individuals make connections with other young vets in their regions. The BVA’s support includes funding to set up regional groups and run meetings, and a dedicated team to act as a point of contact for YVN groups to help to establish and facilitate new groups throughout the UK, both via social media and through physical meetings, and to signpost resources that are available to vets to help them in their early careers, including with their mental health and wellbeing.
As a member of the RCVS-led Mind Matters Initiative, the BVA is also calling on the profession as a whole to help support the next generation of veterinary surgeons and urging employers and managers to make use of a wide range of practical resources available to help with PDP and mentoring recent graduates. These include:
BVA President Sean Wensley said: "These statistics present a sobering challenge to the veterinary profession and it is essential that we all take steps to support our colleagues. We all have a role to play in making veterinary workplaces supportive and nurturing places for recent graduates. Through the Young Vet Network, BVA is taking a lead to help graduates fulfil their potential as veterinary surgeons, helping them cope with the pressures of the job in their early careers.
"We know we are not alone – there is some fantastic work going on, with some employers embracing PDP and practices making innovative and positive use of ideas such as reflective practice sessions. But clearly this isn’t happening everywhere and we need to make sure good practice is widely disseminated and replicated so we urge everyone to make use of the resources and guides available.
"By investing in students and recent graduates we are investing in our future as a profession. We need to ensure that all vets who need support have access to it and know where to seek help if they need it. I would encourage any colleague with concerns about their mental wellbeing to use the Vetlife helpline and confidential email service."
Anyone interested in setting up a YVN group, including funding support, should contact Tim Keen at timk@bva.co.uk or call 020 7908 6343.
Norbrook Laboratories has launched Closamectin, a parasiticide which the company says will revolutionise cattle farming and parasite control in meat producing animals.
Closamectin Pour-on is a solution which can quite literally be poured onto the back of animals. It simultaneously treats fluke, worms and external parasites. The new product is the culmination of a six year research project costing £3.5 million and involving 80 scientists at the company's headquarters in Newry Co Down.
Norbrook says it will bring immense benefits for farmers whose cattle are often ravaged by parasitic attack. Fluke in particular can have devastating effects both on beef and dairy herds, seriously weakening, and in some cases killing the animals by destroying their livers. At the very least it collectively costs farmers around £17 million per annum by reducing the weight of beef cattle and the milk yields of dairy cows.
Fluke used to be confined to the western parts of Britain, together with Scotland and Ireland, but global warming has seen other parts of the UK experiencing the same mild and wet conditions on which the parasite thrives. Consequently it is on the rise.
Currently fluke is treated by injection or oral drench - both time-consuming and difficult processes for the farmers which can also be stressful for the animals. In contrast pour-on solutions can be applied swiftly and easily with no detrimental impact on cattle.
Norbrook has been awarded licenses for Closamectin Pour-on in both the UK and Ireland. This is a very significant market: the countries have a combined cattle population of 17 million. There are also plans to roll out the product in other countries.
Developing a pour-on to deal with these parasites has baffled scientists for 20 years. Alistair Couper, Norbrook's Chief Vet said: "This is the Holy Grail of farm animal veterinary medicine. It was a highly complex challenge for our research team. They had to develop a product which would treat different conditions simultaneously and have a molecular structure which could be absorbed straight through the skin. This is a ground breaking achievement and a brilliant piece of science"
Lord Ballyedmond, Chairman of Norbrook Laboratories said: "This is a very important milestone for Norbrook and for livestock and farmers worldwide. We have invested heavily in research and development and the results are there for all to see. We are delighted to have beaten other multinationals. We have now developed the world's most effective remedy for parasite control in cattle that our entering the food chain. I am pleased to state that our business has grown this year indigenously at 12% despite the recession, beating our competitors. This tremendous breakthrough is a great testimony to the brilliance of our scientists in Newry and also to our policy of investing in research. "
Eurovet Animal Health has announced that its levothyroxine tablet hypothyroidism treatments, Forthyron 200 and Forthyron 400, are now available in a scored snap-tab format that allows the tablet to be broken easily into four equal pieces.
Eurovet says this represents a significant benefit to practices, as individual patients often require varying doses due to differences in absorption and metabolism, requiring a wide variety of strengths of medication to be kept in stock. The new presentation means that veterinary surgeons can provide the accurate, customized, individualised approach that these patients require and since just two strengths need to be stocked, it is easier to manage the dispensary. This saves the practice time and money.
Forthyron contains levothyroxine, a synthetic product, chemically identical to naturally occurring T4 that, due to its long duration of action, is a commonly used treatment for hypothyroidism in dogs.
For further information telephone 01223 257933 or email office@eurovet-ah.co.uk www.eurovet-ah.co.uk
Isle of Wight based veterinary surgeon Dan Forster has had his mobile practice named as the best Business to Consumer Start-up at the inaugural Ready for Business Awards 2013.
Dan launched The Mobile Vet in June 2013, since when he has treated patients from across the Isle of Wight and allowed members of the community who may have been unable to take their pets to the vets for years due to illness or age-related conditions access care for their animals. He says his service has also reactivated many dormant patients who had not visited a vet for many years and had fallen behind with vaccinations, plus those who had decided not to visit because their pets were too nervous or aggressive. Apparently, the service has also gone down well with busy families and households with multiple pets.
The judging panel included David Hitchcock of Barclays, Amanda Hurford from the Department for Business, Innovation and Skills and Titus Sharpe, chief executive of MVF Global and winner of the Sunday Times Tech Track 2013. They selected The Mobile Vet as the winner due to its innovative approach whilst still offering all the traditional veterinary services its customers require. The judges were also impressed by its potential for growth, not just in the South East, but possibly throughout the UK and its drive to continually invest in the latest equipment and create additional job opportunities.
Dan said: "We are truly delighted to have our achievements recognised with such a prestigious accolade so soon after launching The Mobile Vet. The help we received to get started and the on-going support available to us has made it possible to develop our idea into a thriving business operation and we now look forward to pushing ahead with our plans for the future."
Kevin Horne, chairman of the Cavendish Consortium added: "In what was a highly competitive category, The Mobile Vet stood out as offering a very difference proposition to its customers and demonstrated a clear understanding of the needs of its clients. We were impressed by the drive and determination shown by Dan and his colleagues to make what is an extremely novel idea a business reality and wish them, and all the other worthy finalists, well as they strive forward."
Locum vets can now come and update their VetSurgeon Profile to display their location and a business card on a map of the UK which practices can browse when they need a locum (NB. login required to see the locums on the map).
Clicking on a locum’s flag on the VetSurgeon Locum Map reveals a summary profile and the distance they can travel. There are plans to add more detail in the future.
VetSurgeon.org Editor Arlo Guthrie said: "This is all part of our programme of ongoing development with VetSurgeon Jobs, to make sure it is the ‘go to’ place for anyone looking to hire a veterinary surgeon or find a job.
"Whilst I’m here, I’d like to thank the practices and businesses that have already advertised on VetSurgeon Jobs. Your continued support is what allows us to develop these kinds of new features, all designed to help lower your recruitment costs."
This year, 13 veterinary surgeons stood for three available places on Council.
6,583 veterinary surgeons voted, a turnout of 18.6% which was significantly down on previous years (24.5% in 2021, 26.2% in 2020 and 25.5% in 2019).
Sue Paterson led the field with 2,358 votes, Olivia Cook came in second with 1,994 votes and Abbie Calow was close behind with 1,820 votes.
Eleanor Ferguson, RCVS Registrar and Returning Officer for both elections, said: “Many congratulations to all successful candidates, who we look forward to welcoming on to RCVS and VN Councils in July.
"Thank you once again this year to everyone who made the decision to stand in this year’s elections and to those who took the time to vote for their preferred candidates.
"We’re not exactly sure why both elections saw falling turnouts this year, but we do appreciate how extremely busy the professions are at the moment, and that everyone’s time is at a premium.
"As part of our ‘Council culture’ project we are looking at ways of improving all aspects of communicating the work around RCVS Council, VN Council and their committees, including around standing for and voting in elections.”
The full results for the RCVS Council election can be found on the 2022 election page.
Andrew, who graduated in 2002 from The University of Bristol, started as a farm vet in Devon and Cornwall, which is where he first became interested in cardiology.
He went on to undergo Specialist Training at The University of Edinburgh and then spent four years working in the pharmaceutical industry.
Andrew then spent almost two years as Head of Cardiology at a large referral hospital in Winchester, before leaving to co-found the first ever video consulting platform for pet owners, Pawsquad.
Since then, he has led teams in some of the largest specialist veterinary referral hospitals in Europe.
More recently, Andrew has run his own specialist-led visiting cardiology service, providing clinical consultancy services to 50 veterinary practices across the south of England for the last five years.
Andrew has been an EBVS European Veterinary Specialist in Small Animal Cardiology and a RCVS Recognised Specialist in Veterinary Cardiology for 10 years.
At Lumbry Park, Andrew plans to use his new role to provide specialist-led care to pets from across the South of England, and to provide cardiac clinical input for the multi-disciplinary team at Lumbry Park who manage patients with some of the most complex clinical problems in the country.
www.lumbrypark.co.uk